antiviral therapy to reduce the risk of transmission to partners (1, 4) . Certainly, a positive HSV-2 result generally equates to a diagnosis of genital herpes. However, because specificity of TSS is not 100%, false-positive results will occur. For example, when used in pregnant women, the HerpeSelect-2 kit (Focus Technologies, USA) has a specificity of 96%, which means that of every 100 positive tests, four of these will be falsely positive (Table 1 
, Ratnam et al).
If the overall prevalence of HSV-2 antibodies in pregnant women in Newfoundland and Labrador is 6%, the positive predictive value (PPV) of this test is only 61%. Can a PPV of 61% allow a physician to confidently say that the patient is infected with HSV-2 and no longer at risk for primary infection?
Conversely, a negative HSV-2 result does not rule out the diagnosis of genital herpes because the patient may have an HSV-1 infection to account for symptoms. In fact, as acknowledged by Ratnam et al, there is an increasing prevalence of HSV-1 as the cause of genital herpes in some regions of the country. In Nova Scotia, the majority of genital swabs in young people are positive for HSV-1, not HSV-2. However, what does a positive HSV-1 serology result mean? This may represent an orolabial infection, and not genital herpes at all. The absence of a history of cold sores is unhelpful because as with genital infections, many people who have orolabial infections are unaware that they have been infected. Differentiation of these two possibilities is often impossible, making a positive HSV-1 result unhelpful. Ratnam et al suggest that a positive result provides the opportunity for counselling regarding transmission via oral and genital sex. However, if the patient has HSV-1 antibodies generated by orolabial HSV-1 infection, to suggest that these antibodies protect them from subsequent HSV-1 genital infection may not be completely accurate. Instances of autoinoculation of HSV-1 from an While the recommendations on the use of serological tests focus on selective populations thought to benefit the most from serodiagnosis, how exactly these tests should be used remains controversial (5) (6) (7) (8) (9) (10) (11) (12) . Although Ratnam et al have provided a comprehensive review of the literature on HSV TSS, a number of recommendations merit further consideration.
• Ratnam et al suggest that "TSS should be performed or repeated on specimens collected at least six weeks after exposure to ensure that the antibody response has occurred". However, it is unclear what is to be considered an exposure. Because the prevalence of HSV-2 in many areas may be 20% and for HSV-1 it could be 50% to 80% (13) , there is a one in five chance that unprotected intercourse, or a greater than one in two chance that oral sex, with any new partner would equate to HSV exposure. Given that infected individuals only shed the virus intermittently, the risk would obviously not be this high. However, it is unclear what the risk of acquiring HSV is from one sexual encounter or how many people would need to be screened to diagnose one infection.
• Ratnam et al also suggest that HSV-2 TSS be offered to those diagnosed with HIV, a measure that "could provide the opportunity to improve health outcome and also serve as an adjunct to risk-reduction counselling". The prevalence of HSV-2 in HIVinfected individuals is indeed higher than the general population and, thus, the PPV of the test will be higher (13) . Data also suggest that HSV-2 facilitates the acquisition of HIV and that suppression of HSV can reduce the HIV viral load, potentially reducing the risk of transmission of HIV (14) (15) (16) . Chronic suppressive therapy using daily valacyclovir has been shown to decrease plasma and genital levels of HIV RNA in women dually infected with HSV-2 and HIV (16) . However, whether knowledge of patients' HSV serostatus translates into adopting risk-reduction strategies is unclear and unproven. For example, if an HIV-infected patient has not modified behaviours on the basis of his or her HIV status, is it realistic to expect that the documentation of HSV-2 infection would yield behavioural changes?
• In regard to offering HSV TSS testing as an opportunity to improve the health of HIV-infected individuals, I would speculate that the majority of those in whom HSV-2 infection has had a significant negative impact have identifiable outbreaks that can be diagnosed with molecular methods. There is no indication for treatment of asymptomatic HSV in persons with HIV. In fact, HSV-suppressive therapy with acyclovir in immunosuppressed individuals is associated with higher rates of resistance than in those who are immunocompetent (17) . Thus, it warrants consideration that suppressive therapy in an immunosuppressed, asymptomatic individual may not be reasonable and in the long-term, could be harmful. Ratnam et al have put together a comprehensive and timely review. However, multiple issues need consideration when choosing a test and interpreting its result. With any diagnostic test, the prevalence of the disease in the population is essential to interpreting the test result. Clinicians need to be aware of the test limitations and need to consider whether the results influence the treatment or outcome. If the results do not influence the outcomes or management, then testing is a waste of finite health resources and is not indicated. We must also ensure that the reason for ordering the test is evidence-based and not driven by marketing campaigns.
Fundamentally, I see guidelines as an important way to standardize and ensure appropriate testing. Although I understand the basis for the recommendations made by Ratnam et al, I still struggle with identifying where HSV TSS fits into the diagnostic armamentarium of HSV infection; discussions with other clinicians suggest that I am not alone. In the clinical laboratory, we do not reliably get clinical information to help guide decisions on whether the test requested is appropriate. I am unsure how useful HSV TSS would be in the population my laboratory serves, in which the prevalence of genital infection due to HSV-1 is higher than that of HSV-2. A cost-effectiveness analysis taking into consideration the increased costs of testing, the cost of the subsequent interventions (suppressive therapy) and whether the testing influences outcomes needs to be considered if these suggestions are translated into public health policy. My apprehension is that HSV TSS will start in select circumstances but slip into broader practice without the appropriate evidence or cost-benefit analysis to support its use until it becomes a part of routine screening of asymptomatic patients presenting for a sexual health check up or even as a regular part of the annual medical examination.
